iradimed corporation develops, manufactures, markets, and distributes magnetic resonance imaging (mri) compatible medical devices, and related accessories and services in the united states and internationally. it offers mri compatible intravenous (iv) infusion pump system with associated disposable iv tubing sets; and mri compatible patient vital signs monitoring system. the company also provides iv poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and spo2 monitoring with sensors and accessories. it serves hospitals, acute care facilities, and outpatient imaging centers. the company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. iradimed corporation was incorporated in 1992 and is headquartered in winter springs, florida.
Company profile
Ticker
IRMD
Exchange
Website
CEO
Leslie McDonnell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRMD stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Mar 24
8-K
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
8 Feb 24
S-8
Registration of securities for employees
13 Dec 23
8-K
IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a
12 Dec 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results
3 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
Transcripts
IRMD
Earnings call transcript
2023 Q4
8 Feb 24
IRMD
Earnings call transcript
2023 Q3
3 Nov 23
IRMD
Earnings call transcript
2023 Q2
3 Aug 23
IRMD
Earnings call transcript
2023 Q1
4 May 23
IRMD
Earnings call transcript
2022 Q4
2 Feb 23
IRMD
Earnings call transcript
2022 Q3
3 Nov 22
IRMD
Earnings call transcript
2022 Q2
29 Jul 22
IRMD
Earnings call transcript
2022 Q1
29 Apr 22
IRMD
Earnings call transcript
2021 Q4
4 Feb 22
IRMD
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
SC 13G/A
Susi Roger E.
13 Feb 24
SC 13G/A
Nine Ten Capital Management LLC
12 Feb 24
SC 13G
BlackRock Inc.
9 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
4
Roger E. Susi
27 Dec 23
4
Roger E. Susi
22 Dec 23
4
Roger E. Susi
20 Dec 23
4
JAMES B HAWKINS
14 Dec 23
144
Notice of proposed sale of securities
14 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.75 mm | 46.75 mm | 46.75 mm | 46.75 mm | 46.75 mm | 46.75 mm |
Cash burn (monthly) | (no burn) | 737.25 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 4.40 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 42.35 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 57.4 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
51.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 111 |
Opened positions | 15 |
Closed positions | 15 |
Increased positions | 46 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 253.51 bn |
Total shares | 6.52 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Nine Ten Capital Management | 771.31 k | $34.22 bn |
Soleus Capital Master Fund | 742.00 k | $0.00 |
Soleus Capital Management | 628.21 k | $27.87 bn |
BLK Blackrock | 613.67 k | $27.23 bn |
Renaissance Technologies | 574.91 k | $25.47 bn |
Vanguard | 412.15 k | $18.29 bn |
RK Capital Management | 300.80 k | $13.35 bn |
Ranger Investment Management | 212.15 k | $9.41 bn |
Dimensional Fund Advisors | 208.85 k | $9.27 bn |
Russell Investments | 206.57 k | $9.17 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Dec 23 | Susi Roger E. | Common Stock | Sell | Dispose S | Yes | Yes | 46.5094 | 5,000 | 232.55 k | 162,950 |
26 Dec 23 | Susi Roger E. | Common Stock | Sell | Dispose S | Yes | Yes | 46 | 5,000 | 230.00 k | 167,950 |
21 Dec 23 | Susi Roger E. | Common Stock | Gift | Dispose G | Yes | No | 0 | 300,000 | 0.00 | 2,062,500 |
19 Dec 23 | Susi Roger E. | Common Stock | Sell | Dispose S | Yes | Yes | 45.1393 | 5,000 | 225.70 k | 172,950 |
18 Dec 23 | Susi Roger E. | Common Stock | Sell | Dispose S | Yes | Yes | 44.0805 | 5,000 | 220.40 k | 177,950 |
14 Dec 23 | Hawkins James B | Common Stock | Sell | Dispose S | No | No | 44.5843 | 4,277 | 190.69 k | 39,348 |
14 Dec 23 | Hawkins James B | Common Stock | Grant | Acquire A | No | No | 9.84 | 4,277 | 42.09 k | 43,625 |
14 Dec 23 | Hawkins James B | Stock Options Common Stock | Option exercise | Dispose M | No | No | 9.84 | 4,277 | 42.09 k | 0 |
13 Dec 23 | Hawkins James B | Common Stock | Sell | Dispose S | No | No | 43.6137 | 219 | 9.55 k | 39,348 |
13 Dec 23 | Hawkins James B | Common Stock | Grant | Acquire A | No | No | 9.84 | 219 | 2.15 k | 39,567 |
News
iRadimed Q4 Adjusted EPS $0.39 Misses $0.40 Estimate, Sales $17.45M Beat $17.33M Estimate
8 Feb 24
Earnings Scheduled For February 8, 2024
8 Feb 24
iRadimed's Earnings Outlook
7 Feb 24
IRADIMED CORPORATION Reports Unaudited Q4 Revenue $17.5M Vs $17.13M Est.; FY23 Revenue $65.6M Vs $65.07M Est.
9 Jan 24